Posttranslational regulation of mitochondrial frataxin and identification of compounds that increase frataxin levels in Friedreich’s ataxia

Received for publication, December 18, 2021, and in revised form, April 18, 2022 Published, Papers in Press, April 25, 2022, https://doi.org/10.1016/j.jbc.2022.101982

Peter T. Hackett, Xuan Jia, Liangtao Li, and Diane M. Ward*
From the Department of Pathology, Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, Utah, USA

Edited by Ursula Jakob

Friedreich’s ataxia (FRDA) is a degenerative disease caused by a decrease in the mitochondrial protein frataxin (Fxn), which is involved in iron–sulfur cluster (ISC) synthesis. Diminutions in Fxn result in decreased ISC synthesis, increased mitochondrial iron accumulation, and impaired mitochondrial function. Here, we show that conditions that result in increased mitochondrial reactive oxygen species in yeast or mammalian cell culture give rise to increased turnover of Fxn but not of other ISC synthesis proteins. We demonstrate that the mitochondrial Lon protease is involved in Fxn degradation and that iron export through the mitochondrial metal transporter Mmt1 protects yeast Fxn from degradation. We also determined that when FRDA fibroblasts were grown in media containing elevated iron, mitochondrial reactive oxygen species increased and Fxn decreased compared to WT fibroblasts. Furthermore, we screened a library of FDA-approved compounds and identified 38 compounds that increased yeast Fxn levels, including theazole bifonazole, antiparasitic 4-hydroxychalcone, and a nonspecific anion channel inhibitor 4,4-diisothiocyanostilbene-2,2-sulfonic acid. We show that top hits 4-hydroxychalcone and dibenzoylmethane increased mRNA levels of transcription factor nuclear erythroid 2–related factor 2 in FRDA patient-derived fibroblasts, as well as downstream antioxidant targets thioredoxin, glutathione reductase, and superoxide dismutase 2. Taken together, these findings reveal that FRDA progression may be in part due to oxidant-mediated decreases in Fxn and that some approved compounds may be effective in increasing mitochondrial Fxn in FRDA, delaying disease progression.

The ability to synthesize Fe–S clusters (ISCs) is an essential process for all eukaryotes and most prokaryotes. ISCs act as prosthetic groups in many proteins including enzymes such as aconitase, DNA repair enzymes, and electron transport proteins (for review see (1)). Defects in mitochondrial ISC synthesis result in human diseases including Friedreich’s ataxia (FRDA), sideroblastic anemia with ataxia, and myopathy with ISCU deficiency (for review see (2, 3)). FRDA is a progressive disease that affects multiple tissues with the most pronounced phenotypes in neuromuscular and cardiac tissue (4–7). The mutated gene responsible for FRDA is FXN, which encodes for the highly conserved mitochondria ISC protein frataxin (Fxns) (8, 9). FRDA patients have markedly reduced levels of Fxn, which result in diminished ISC synthesis, increased mitochondrial iron, and elevated mitochondrial reactive oxygen species (ROS) and biochemical changes that have been shown in both cardiac tissue of FRDA patients and FRDA animal models (10–14). Mature Fxn in the mitochondrial matrix has been shown to interact with ISC assembly enzyme Iscu and the cysteine desulfurase Nfs1 to increase the activity of Nfs1 (15–17).

In FRDA, most patients have reduced levels of Fxn due to an intron expansion that results in reduced transcripts (18, 19). However, a wide range of missense and nonsense mutations affecting Fxn levels have also been reported (20–22). The severity of the disease is directly correlated with the levels of mature mitochondrial Fxn. Recent studies have shown decreased Fxn levels can result from causes other than mutations in the FXXN gene. Doxorubicin treatment of mammalian cardiac cells has been shown to result in decreased Fxn levels due to increased Fxn degradation (23, 24). More recently, studies in yeast have shown that mutations in ERG29 lead to increased levels of 4’-methyl sterol intermediates leading to an iron-dependent oxidation of mitochondrial Yfh1 (the yeast Fxn homolog) resulting in decreased Yfh1 levels, decreased ISC production, and impaired viability and cell growth (25, 26). Many studies have implicated elevated levels of ROS in FRDA pathology (27, 28). Here, we show that increased mitochondrial ROS resulted in a decrease in mitochondrial Yfh1 half-life due to degradation by the mitochondrial Lon protease Pim1. We also showed that increasing mitochondrial iron export through overexpression of the mitochondrial iron exporter MMT1 (29, 30) preserved Yfh1 levels even in the absence of Erg29. We confirmed that increased mitochondrial ROS gave rise to decreased mammalian Fxn while partner proteins Iscu and Nfs1 levels were unchanged in the H9C2 cardiomyocyte doxorubicin model. We demonstrated that FRDA patient fibroblasts were more susceptible to iron-dependent Fxn degradation and that inhibiting the Lon protease protected

* For correspondence: Diane M. Ward, diane.mcveyward@path.utah.edu.
Mitochondrial turnover of frataxin

mammalian mitochondrial Fxn from ROS-induced degradation. We screened a library of the Food and Drug Administration (FDA)-approved compounds for their ability to increase yeast Yfh1 levels when ERG29 expression was shut off and identified compounds that increased Yfh1 levels and cell growth. Compounds that showed the highest efficacy in yeast also showed increased mature mitochondrial Fxn levels in doxorubicin-treated cardiomyocytes and FRDA fibroblasts. Our data provide a possible explanation for the progression of disease in FRDA due to further loss of Fxn, and we identify compounds that may be efficacious in slowing the progression of FRDA.

Results

Yfh1 half-life is decreased and mitochondrial ROS appear rapidly after loss of ERG29 expression

Previously, we reported that loss of Erg29, a protein involved in ergosterol synthesis in yeast, resulted in mitochondrial dysfunction and decreases in the ISC synthesis protein Yfh1 (26). We reported that the decrease in Yfh1 protein levels was not due to a change in YFH1 transcripts (26), suggesting that the change in Yfh1 levels was due to posttranslational regulation. To determine if the half-life of mitochondrial Yfh1 was altered, we generated a Δerg29 yeast strain containing a plasmid with expression of ERG29 regulated by the GAL1 promoter. In the presence of galactose, cells express ERG29 (ON) and when grown in glucose as a carbon source, ERG29 is not expressed (OFF). The strain also contains the coding sequence of GFP cloned in frame into the carboxyl terminus of the endogenous locus of YFH1. We refer to this strain as ERG29 YFH1-GFP shut off cells. Yfh1-GFP was found to localize to the mitochondria as previously reported (Fig. S1) (25). We grew these cells in galactose (ON) and then shifted them to glucose (OFF) in the presence of cycloheximide to block new translation. We observed a significant diminution in Yfh1-GFP levels in ERG29 OFF cells compared to ERG29 ON cells (Fig. 1A). Quantification of Western blots revealed that the half-life of Yfh1-GFP in ERG29 ON cells (5.10 h) was similar to that previously reported for Yfh1 (4.9 h) (31) (Fig. 1B). In ERG29 OFF cells, we observed a rapid decrease in the half-life of mitochondrial Yfh1-GFP (2.94 h), whereas the half-lives of Nfs1 and Isu1, other ISC synthesis proteins that act in the early ISC assembly complex (32, 33), were unaltered. The amount of Nfs1 and Isu1 found complexed to Yfh1-GFP in control cells (ERG29 ON) was about 20 to 30%, with 70 to 80% unbound at any given time (Fig. 1C). As expected, the levels of unbound Nfs1 and Isu1 increased in the ERG29 shut off cells. The change in Yfh1 half-life was observed almost immediately after turn off of ERG29 expression, suggesting that there is either a signal or modification on Yfh1 that mediates increased turnover. The decreases in Yfh1 levels seen as early as 2 h after ERG29 shut off resulted in increased mitochondrial ROS as measured by the Mitox SOX mean fluorescence intensity (Fig. 1D) and diminished ISC synthesis as measured by aconitase activity (Fig. 1E). This result suggests that the levels of Yfh1 can be “rate-limiting” for ISC synthesis. We also noted that control cells grown in galactose showed reduced aconitase activity suggesting that ISC synthesis may not meet the demands required by growth in galactose.

The Lon protease Pim1 is responsible for increased turnover of Yfh1 under mitochondrial oxidative stress

Previous studies suggest that immature Fxn levels can be changed by inhibiting specific protease pathways in mammalian FRDA cells including the proteasome and autophagy pathways along with inhibiting the mitochondrial protease PITRM1 (34–37). Mitochondria possess several different protease systems to maintain mitochondrial homeostasis and cellular health (38–42). We focused on the Lon protease Pim1, a yeast mitochondrial protease known to mediate oxidized protein turnover (43, 44). To determine if Pim1 is responsible for increased Yfh1 turnover in ERG29 OFF cells, we generated strains expressing YFH1-GFP with a deletion of PIM1 in WT and Δerg29pGAL1ERG29 cells. Loss of Pim1 resulted in a slight increase in Yfh1-GFP half-life in WT mitochondria, although not to significance (Fig. 2A), whereas, deletion of PIM1 in Δerg29pGAL1ERG29 shut off cells resulted in a dramatic increase in the half-life of mitochondrial localized Yfh1-GFP with minimal Yfh1-GFP degradation observed when ERG29 was shut off (Fig. 2B). In addition, overexpression of the mitochondrial iron exporter Mmt1 protected Yfh1 from Pim1-mediated degradation in ERG29 OFF conditions (Fig. 2C). These results suggest that mitochondrial iron accumulation and increased mitochondrial oxidant-mediated targeting of Yfh1 are responsible for increased Yfh1 degradation through Pim1.

Mammalian Fxn levels are reduced in doxorubicin-treated cardiomyocytes and iron-loaded FRDA fibroblasts

Previous studies have shown doxorubicin treatment of cardiomyocytes results in increased mitochondrial ROS, decreased Fxn levels, and decreased mitochondrial function (23, 45, 46). Overexpression of Fxn protects against oxidant-mediated cell death. We examined if other ISC synthesis proteins were affected by doxorubicin exposure. When the rat cardiomyocyte cell line H9C2 was treated with doxorubicin, there was a marked decrease in Fxn levels, whereas, levels of the ISC scaffolding protein Iscu increased and Nfs1 levels were unaltered (Fig. 3, A and B). (Quantification of Western blots was done on mature Fxn). This suggests that the increased mitochondrial ROS in doxorubicin-treated cardiomyocytes specifically affect Fxn levels, similar to what we observed in our yeast ERG29 shut off model (Figs. 1 and 2).

It is important to note that decreases in Fxn levels below 50% have been shown to result in mitochondrial iron accumulation in yeast cells and in mammalian models of ISC defects (25, 47, 48). We hypothesized that increasing iron levels in the mitochondrial of FRDA patients would further reduce mitochondrial Fxn levels. To our knowledge, the levels of mitochondrial Fxn over time of concurrent mitochondrial iron accumulation in patients have not been evaluated. To test this hypothesis, we grew WT and FRDA fibroblasts in 20 μM
Fe-nitrotriacetic acid (FeNTA) and measured Fxn levels and mitochondrial ROS. Fxn levels were increased in WT cells grown in the presence of FeNTA (Fig. 3, C and D). In contrast, Fxn levels were significantly reduced in FRDA cells under these same conditions. Both WT and FRDA showed increased levels of ferritin, indicating that both WT and FRDA cells were iron loaded. To determine if the changes in Fxn levels were due to changes in transcripts, we quantified FXN mRNA levels using reverse transcription quantitative PCR (RT-qPCR). We observed a small but significant increased FXN transcripts in FeNTA grown FRDA cells (Fig. 3E). These results show that the decrease in Fxn protein in FeNTA-exposed FRDA cells was not due to a decrease in FXN transcripts. The increase in cellular iron levels slightly increased mitochondrial ROS in WT cells and dramatically increased mitochondrial ROS in FRDA cells (Fig. 3, F and G). Our yeast studies showed that when mitochondrial ROS were increased due to iron accumulation, yeast Fxn (Yfh1) was degraded by the Lon protease Pim1 (Fig. 2), which is known to target oxidized proteins (49). To determine if mammalian Fxn is a target of the Lon protease, we utilized a Lon protease inhibitor 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO–Me) to prevent degradation of oxidized mitochondrial proteins (50). We confirmed that the CDDO-Me acted as a Lon inhibitor as the levels of a known Lon target, aconitase 2 (51, 52), were increased when FRDA cells were treated with CDDO-Me (Fig. S3). When FRDA cells grown in FeNTA were treated with CDDO-me, we observed a significant increase in Fxn levels (Fig. 3H). These results support a role for the Lon protease in mitochondrial iron/oxidant-mediated decreased Fxn levels similar to that observed in yeast (Fig. 2) and for other yeast ISC proteins (53). As expected, the levels of Fxn did not approach

Figure 1. Loss of Erg29 results in a reduced half-life for Yfh1. A. Δerg29pGAL1ERG29YFH1-GFP cells were grown overnight in galactose (ON) (black) and then shifted to glucose (OFF) (red) in the presence of 100 μM cycloheximide for 0 to 8 h. Mitochondria were isolated and Yfh1-GFP, Nfs1, Isu1, and Porin levels determined by Western blot. Porin levels were used as a loading control. A time course of representative blots for Yfh1-GFP, Nfs1, Isu1, and Porin from the same experiment are shown. n = 3. B. Western blots from three biologic replicate experiments were quantified and graphed as described in Experimental procedures. Half-lives were determined for Yfh1-GFP, Nfs1, and Isu1 as described in Experimental procedures using one-phase decay. C. Yfh1-GFP was immunopurified from samples as in (A) and Yfh1-GFP, Nfs1, and Isu1 levels in the immunopurification determined. A representative blot is shown. The data are graphed as the percent remaining in the flow through. D. mitochondrial ROS were measured in cells as in (A) using MitoSOX as described (26). A representative flow plot is shown for the 0 and 8 h time points. The mean fluorescence intensity (MFI) was determined over time of ERG29 shut off compared to ERG29 ON cells. n = 3 replicate experiments. E, aconitase levels were determined as described previously (26) from WT (control) and Δerg29pGAL1ERG29YFH1-GFP cells grown in galactose and shifted to glucose (OFF) for 0, 2, or 8 h. Error bars in all panels represent SEM (n ≥ 3 biologic replicate experiments). FT, flow through; IP, immunopurification; L, total lysate; ROS, reaction oxygen species.
that of WT fibroblasts as the genetic mutation harbored in FRDA patient cells already shows a >50% decrease in Fxn due to reduced FXN mRNA levels. Fxn levels did return to pre iron exposure levels. We noted that extended incubations (>24 h) with 1 μM CDDO-Me were toxic to cells (data not shown) not allowing for extended time course evaluations of Fxn turnover.

**Screen for compounds that increase Fxn levels**

Current therapies for FRDA have shown modest effects in vivo and there is a great need for better therapies for this lethal disorder. Studies have suggested that iron chelation, antioxidants, or increased autophagy may improve mitochondrial function in either the absence of Yfh1 (54, 55) or when Fxn levels are reduced in FRDA (56, 57). Our data suggest that increasing or stabilizing Fxn protein levels is an extremely attractive approach to treat the progression of FRDA. We used our unique ERG29 YFH1-GFP shut off yeast strain to identify compounds from a 2500 FDA-approved library that increased Yfh1-GFP fluorescence. 

**Figure 2. Pim1 is responsible for mitochondrial Yfh1 degradation in ERG29 shut off cells.** A, WT (black) and Δpim1 (red) cell containing genomically tagged YFH1-GFP were grown in galactose and shifted to glucose in the presence of 100 μM cycloheximide for time, mitochondria isolated, and Yfh1-GFP and Porin levels determined by Western blot as in Figure 1. Representative blots are shown. Quantification was done as described in Experimental procedures. n = 3 replicate experiments. B, levels of Yfh1-GFP and Porin were determined in Δerg29pGAL1ERG29 (black) and Δerg29pGAL1ERG29Δpim1 (blue) containing genomically tagged YFH1–GFP grown in glucose ± 50 nM β-estradiol as previously described (26). The removal of β-estradiol mimics galactose to glucose shut off of ERG29. This was done in the presence of 100 μM cycloheximide for time as in (A). C, levels of Yfh1-GFP and Porin were determined in Δerg29pGAL1ERG29 (black) and Δerg29pGAL1ERG29pMMT1 (green) grown as in (A). Representative Western blots are shown for each. All blots were quantified using Fiji ImageJ software and the changes in Yfh1–GFP determined over time using Porin as a control. Error bars in all panels represent SEM (n ≥ 3 replicate experiments). ROS, reaction oxygen species.
compounds were grouped according to their predicted mechanism of action (Fig. 4A). Compounds that showed autofluorescence (e.g., reserpine) were eliminated from further analysis. The optimum concentration (1–20 μM) for top compounds from each group was determined (Figs. S4B and 4B). We note that the concentration curve heat map for the top compounds did not consistently rank the compounds; however, all compounds showed increases in Yfh1-GFP as shown by Western blot analysis quantification (Fig. 4C). Increases in Yfh1-GFP could be the results of increased

Figure 3. Frataxin levels are reduced in doxorubicin exposed cardiomyocytes and FRDA fibroblast exposed to increased iron. A, rat H9C2 cells were incubated with or without 10 μM doxorubicin for 48 h, cells were harvested, washed in PBS, lysed in 1% Triton X-100, 150 mM NaCl, 10 mM Tris–HCl, 0.5 mM Na4EDTA pH 7.2, 0 °C, 30 min, and centrifuged for 30 min at 14,000g. Supernatants were boiled in SDS-PAGE loading buffer, run on 4 to 20 SDS-PAGE and Fxn, Nfs1, Iscu, and GAPDH levels determined by Western blot. A representative blot with three replicates is shown. n = 3 replicate experiments. B, blots from (A) were quantified using GAPDH as a loading control and data normalized to 1.0 using samples without doxorubicin as a control. Error bars represent SEM (n = 3 replicate experiments). C, WT and FRDA fibroblasts were grown in the absence or presence of 20 μM FeNTA for 48 h, harvested, and lysed as described in (A) and Fxn, ferritin, and GAPDH levels determined by Western blot. Representative blots with four experimental replicates are shown. n = 4 replicate experiments. D, Western blots from (C) were quantified as described in Experimental procedures and data normalized to 1.0 using WT samples without FeNTA as the control. Error bars represent SEM (n = 4 replicate experiments). E, Fxn and ACTB transcript levels from cells as in (C) were quantified using RT-qPCR as described in Experimental procedures. (n = 3 replicate experiments with 3–4 technical replicates/experiment). F, mitochondrial ROS were determined using MitoSOX in FRDA cells as in (C) with an example graph shown for WT and FRDA ± Fe. G, MitoSOX values from five biologic replicates as in (F) were graphed and expressed as the MFI. H, cells grown in supplemental FeNTA as in (C) were treated with the Lon1 protease inhibitor CDDO-Me (1.0 μM) for 24 h and Fxn and GAPDH levels determined and quantified n = 4 replicate experiments. CDDO, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid 9; FeNTA, Fe-nitrotriacetic acid; FRDA, Friedreich's ataxia; Fxn, frataxin; ROS, reactive oxygen species; RT-qPCR, reverse transcription quantitative PCR.
transcription, increased mRNA stability, increased translation, or increased protein stability. To determine if compounds altered YFH1 transcripts, we performed RT-qPCR on cells grown in the presence or absence of the top six compounds. YFH1 expression was not significantly increased in cells treated with compounds (Fig. 4D). To test if the compounds affected YFH1-GFP translation or protein stability, we tested compound efficacy in the presence or absence of cycloheximide. Most compounds showed an inhibition in compound-mediated increases in Yfh1-GFP in the presence of cycloheximide (Fig. 4E) supporting that these compounds may be increasing YFH1-GFP translation. In contrast, incubation with cycloheximide did not prohibit the 4,4-diisothiocyanostilbene-2,2-sulfonic acid (DIDS)—mediated increases in Yfh1-GFP. This suggests that DIDS is working posttranslationally. We recognized the caveat that cycloheximide might be affecting the translation of other proteins that impact Yfh1-GFP levels. One prediction of having increased Yfh1 levels is improved ISC synthesis. Indeed, treatment with top compounds including bifonazole, fipronil, cetylpyridinium chloride (CPCL), dibenzoylmethane (DBM), and 4′-hydroxychalcone (4′-OHC) increased ISC synthesis as measured by aconitate activity (Fig. 4F). These results confirm that our yeast screen successfully identified compounds that increased Yfh1 levels and ISC synthesis in yeast. It was surprising that aconitate activity was not increased by DIDS. In fact, aconitate activity...
was reduced by 50% in ERG29 ON cells treated with DIDS, suggesting that DIDS affects aconitase activity independent of the cells used (Fig. 5A). We do not know the mechanism of reduced aconitase activity due to DIDS.

**Compounds show increased levels of Fxn in doxorubicin-mediated cardiomyocyte toxicity and in iron-loaded FRDA fibroblasts**

To establish if any of the compounds identified showed efficacy in mammalian cells, we utilized two models, the doxorubicin cardiomyocyte model of reduced Fxn levels (23) and FRDA patient fibroblasts. The rat cardiomyocyte cell line H9C2 was grown in the presence or absence of doxorubicin and different concentrations of the top compound DBM and Fxn levels determined by Western blot. Fxn levels in doxorubicin-treated cells showed a concentration-dependent increase in the presence of DBM (Fig. 5A). Fxn levels were also increased with DIDS, bifonazole, and fipronil, although higher levels of bifonazole and fipronil were toxic (Fig. 5B). In contrast, neither 4′-OHC nor CPCL showed efficacy in increasing Fxn levels in doxorubicin-treated cardiomyocytes. In FRDA cells DIDS, DBM, and 4′-OHC showed increased Fxn levels, while bifonazole showed a trend toward increased Fxn levels, although not to significance (Fig. 6, A and B). DBM and DIDS showed efficacy in both models of decreased Fxn. We speculate that the differences in effectiveness of compounds between cardiomyocytes and FRDA fibroblasts may simply reflect cellular differences in the efficiency of compound uptake. We note that increased Fxn levels in FRDA cells were not the result of increased FXN expression (Fig. 6C) similar to that seen in the yeast system used to original screen compounds. This leaves open the question of the mechanism(s) of action of these compounds in mammalian cells. Most effective compounds showed reduced levels of mitochondrial ROS, although CPCL did not decrease mitochondrial ROS and 4′-OHC was not as effective (Fig. 6D). These results suggest that either compound-induced increases in Fxn itself reduces mitochondrial ROS or compounds may work by increasing antioxidants that then improve Fxn translation or protect Fxn from degradation.

Previous studies have shown that the expression of the antioxidant master regulatory transcription factor nuclear factor erythroid 2–related factor 2 (Nrf2) is diminished in FRDA (58, 59). We hypothesized that some compounds may be working through Nrf2. We confirmed that FRDA cells showed reduced NRF2 expression, which was increased by two compounds, DBM and 4′-OHC (Fig. 6E). We next tested to see if the downstream activation of known transcriptional targets of Nrf2 were affected by the addition of compounds. DBM and 4′-OHC showed efficacy in improving antioxidant target transcripts including TXN and GSR but no increase in SOD2, whereas, 4′-OHC increased expression of all three Nrf2 targets (Fig. 6F). These data support that DBM, fipronil, and 4′-OHC may be working by increasing antioxidants that may protect Fxn from modification and increased turnover in FRDA. That fipronil did not increase Nrf2 but did increase antioxidant transcripts, which suggests that it may be working through a different mechanism to increase antioxidants in FRDA cells. The mechanism of how DIDS is reducing antioxidants and improving Fxn levels remains to be elucidated. Together, our results demonstrate that using yeast to identify compounds that increase Fxn levels in mammalian cell culture is a viable approach to discovering novel potential therapies for the treatment of FRDA.

**Discussion**

In this study, we demonstrate that loss of Erg29 in yeast results in Lon protease Pim1-mediated degradation of yeast Fxn homolog Yfh1, while other ISC synthesis proteins Nfs1 and Isu1 levels are not reduced. We also show that Yfh1 can be

---

**Figure 5. Compounds identified from the screen show efficacy in improving Fxn levels in doxorubicin-treated cardiomyocytes.** A, H9C2 rat cardiomyocytes were cultured in the presence of doxorubicin and 10 to 100 μM DBM for 48 h and Fxn and GAPDH levels determined by Western blot. A representative blot is shown. Quantification of three biologic replicate experiments is shown. B, quantification of changes in response to other top compounds from the screen are shown (n = 3 replicate experiments). DBM, dibenzoylmethane; Fxn, frataxin.
Mitochondrial turnover of frataxin

Figure 6. Top compounds show increased Fxn levels in FRDA fibroblasts. A, WT and FRDA fibroblasts grown in the presence of 20 μM FeNTA were incubated in the absence or presence of selected compounds at the designated concentrations for 48 h and Fxn and GAPDH levels determined by Western blot. Representative blots are shown. B, quantification of three replicate experiments is shown normalized to WT cells. C, Fxn and ACTB transcripts from cells as in (A) were determined using RT-qPCR as described in Experimental procedures. (n = 4 biologic replicate experiments with 3–4 technical replicates/experiment). D, mitochondrial ROS were measured using MitoSOX MFI in FRDA cells treated as in (A). n = 5 biologic replicates are graphed. E, NRF2 and ACTB expression was determined from cells as in (A) (n = 4 biologic replicate experiments with 3–4 technical replicates/experiment). F, transcript levels for three transcriptional targets of NRF2 (TXN, GSR, and SOD2) were determined from cells as in (A). Error bars for represent SEM (n = 3–4 biologic replicate experiments with 3–4 technical replicates/experiment). FeNTA, Fe-nitrotriacetic acid; FRDA, Friedreich’s ataxia; Fxn, frataxin; MFI, mean fluorescence intensity; ROS, reactive oxygen species; RT-qPCR, reverse transcription quantitative PCR.

protected from degradation by prohibiting mitochondrial iron accumulation through the overexpression of the mitochondrial iron exporter Mnt1. These results support the hypothesis that Fxn protein levels are sensitive to mitochondrial iron accumulation and subsequent mitochondrial ROS-mediated modification that increases Fxn turnover. The literature suggests that a decrease in Fxn due to ROS is not restricted to yeast or sterol metabolism but occurs in mammalian cells in response to drugs or conditions that affect mitochondrial ROS. Cardiac toxicity resulting from doxorubicin treatment limits the use of this drug in cancer therapy. It is well known that the toxicity of these types of drugs is iron related, and iron chelation can reduce cardiac toxicity (24, 60, 61). Recent studies demonstrated that doxorubicin decreased Fxn levels and that overexpression of Fxn or decreased mitochondrial iron through overexpression of the putative mitochondrial iron exporter Abcb8 preserved Fxn (23, 24, 61). We note that primary cardiomyocytes show increased doxorubicin toxicity compared to H9C2 cells (62, 63) making it critical to keep this in mind along with doxorubicin concentration utilized when evaluating compound efficacy for potential future studies in primary induced pluripotent stem cell–derived cardiomyocytes. In our current study, we demonstrate that mammalian Fxn shows similar sensitivity to iron-mediated mitochondrial ROS that drives mitochondrial Lon1 protease-mediated Fxn degradation, while other ISC proteins were not reduced under similar conditions. We show this in two mammalian model systems, doxorubicin-mediated toxicity in cardiomyocytes and FRDA fibroblasts grown in elevated levels of media iron. Previous studies have suggested that ISC proteins are potential targets of the Lon protease (64), but to our knowledge, this is first confirmation that Lon protease is involved in mature Fxn turnover. We recognize that inhibition of any protease system can have pleiotropic effects. That we see changes in Fxn levels and no other ISC proteins in the ERG29 OFF or FeNTA grown FRDA cells and that deletion of PIM1 or use of CDDO-Me protects Fxn from increased degradation strongly supports a role for the Lon protease in Fxn turnover. This observation is in contrast with the previous report that Lon was not involved in mature Fxn turnover (37). Perhaps one explanation for the differences in these two studies is that our studies utilized a Δpim1 strain, which has no Lon protease activity, to measure Yfh1 turnover. Further, we also utilized a compound that has been shown to inhibit Lon activity and that overexpressing only Lon1 was sufficient to rescue the effects of CDDO-Me treatment, while the studies of Nabhan et al. utilized siRNA leaving open the possibility of remaining Lon protease activity in those studies. Another notable difference in our studies and those previously reported is that our model conditions show increased mitochondrial ROS in both yeast and mammalian cell culture conditions. That mitochondrial ROS are increased like that seen in FRDA may provide the necessary environment to modify Fxn, making it a target of the Lon protease. Previous in vitro studies have shown that a conserved tryptophan residue Trp155 in human Fxn is a hotspot for oxidative chemical modification (65).
Studies on how Fxn might be modified in our conditions and what residues are modified are a future direction of the lab.

We speculate that when Fxn levels drop below 50% (no phenotypes are associated with a single allele mutation) (8, 9), “free” iron begins accumulating in the mitochondria giving rise to increased mitochondrial ROS and Fxn degradation without the ability to compensate by synthesizing sufficient ISCs. Our results suggest that Fxn acts like a gatekeeper involved in both ISC synthesis as well as sensing mitochondrial ROS inducing “free” iron pools, making it an “Achilles heel” in ISC synthesis and mitochondrial homeostasis. In FRDA, Fxn levels are already at a critically low level, so the discovery that this level can be further reduced due to increased mitochondrial iron and ROS may provide additional guidance on therapeutic interventions to delay disease progression. The use of iron chelators has been suggested for FRDA and studies in model systems have shown some promise (for review see (66)); however, some studies suggest that when ISC synthesis is insufficient, limiting mitochondrial iron by chelation can be detrimental by further limiting ISC synthesis (67). We hypothesize that these contrasting results may be ascribed to “timing” of iron chelation therapy. That is, once Fxn levels and ISC synthesis drop too low, biology selects to increase mitochondrial iron levels as a response to try to improve ISC synthesis. However, if Fxn levels are too low to efficiently make ISC, reducing mitochondrial iron may have deleterious effects by limiting iron for low level ISC synthesis that occurs in FRDA. This suggests that combination therapies that improve Fxn levels and ISC synthesis would be the most effective way to prevent mitochondrial iron accumulation.

The findings of our studies have implications beyond understanding the posttranslational regulation of Fxn. While the role(s) of Fxn remain to be fully elucidated, several reports describe improved consequences to increased levels of Fxn under conditions of increased mitochondrial ROS. (1) Overexpression of Fxn in transgenic flies suppressed the toxic effects of iron, H2O2, and paraquat on lifespan (68). (2) Purified recombinant cell-permeable Fxn (PEP1-Fxn) protected neuronal cells from oxidant-mediated cell death (69). (3) The effects of the Parkinson’s disease inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which targets complex I in the electron transport chain can be suppressed by providing recombinant Tat-Fxn (70). These results underscore that mitochondria are highly susceptible to iron-mediated toxicity and suggest that this toxicity may target ISC formation. We speculate that other compounds/conditions that result in mitochondrial toxicity, through generation of ROS, might also attack ISC synthesis and be suppressed by either removal of mitochondrial iron or increased levels of Fxn. It is important to take into consideration that there may be consequences to “overexpression” of Fxn. Indeed, studies have suggested that if FxN is highly overexpressed there can be significant deleterious consequences (71, 72).

Our studies and compounds discovered recover Fxn levels but not above that seen in untreated WT cells. We report that Fxn levels are increased in response to higher cellular iron levels, but we did not observe any deleterious consequences to this increase in Fxn. We further show that FXN transcripts are increased in response to increased cellular iron. This suggests that one role of Fxn is to protect cells/mitochondria from the consequences of elevated iron, such as when making more ISCs. To our knowledge, the generation of more ISCs is not toxic to cells, and we hypothesize that this may be a way to store iron and provide a level of protection from “free” iron toxicity.

We utilized our novel yeast strain Δerg29pGA-L1ERG29YFH1-GFP to screen for compounds that prevent decreases in yeast Fxn and those compounds showed efficacy in improving Fxn levels in mammalian models including FRDA cells (Fig. 7). We successfully identified compounds that did not affect FXN transcripts but rather affected mature Fxn protein levels. That we did not identify compounds that increased YFH1/FXN transcription may simply reflect the group of top compounds we chose to analyze more extensively. It is also possible that the compound library (2500 FDA approved compounds) did not contain compounds that would be effective in moderating yeast FXN transcription or that increased yeast FXN transcription might be limited in our

Figure 7. Graphic abstract of mitochondrial stress and Fxn turnover in FRDA. Under normal conditions WT mitochondria have an intact ISC machinery and iron import into the mitochondrial occurs at a normal rate. In FRDA, with diminished Fxn or when ISC synthesis is diminished, mitochondrial iron import is increased without improvements in ISC synthesis. This causes iron accumulation in the mitochondrial increased mitochondrial ROS, and decreased Fxn protein levels. We speculated that Fxn is oxidized under these conditions making it susceptible to increased proteolytic degradation in the mitochondria by the Lon protease. We identified novel compounds that increased Fxn levels in FRDA cells that resulted in decreased ROS and increased ISC synthesis. We speculate that these compounds, in combination with other FRDA therapeutics, would delay disease progression. FRDA, Friedreich’s ataxia; Fxn, frataxin; ISC, Fe–S cluster; ROS, reactive oxygen species.
model. We discovered compounds that increased antioxidant gene expression but we also identified compounds, bifonazole and DIDS, that appear to modulate Fxn levels through different mechanisms. Understanding how these compounds are working and discovering multiple pathways to increase Fxn levels may provide a multipronged approach to effective therapies for FRDA. Indeed, a recent study suggests that buffering the oxidative stress associated with FRDA using gold quantum cluster therapy reduced ROS, decreased autophagy, and increased Fxn protein expression providing a novel therapeutic strategy to delay disease progression in FRDA (73). This study along with others and our work reported here suggests that there may be novel therapeutic approaches to reduce disease progression in FRDA.

**Experimental procedures**

**Yeast, plasmids, and growth medium**

Genotypes of strains employed in this study are listed in Table 1. The WT strains employed for these experiments were from the W303 background. Most deletion strains were created by either PCR amplifying the KanMX cassette from the homozygous diploid deletion collection (Research Genetics) or created by either PCR amplifying the KanMX cassette from the W303 background. Most deletion strains were worked and discovered multiple pathways to increase Fxn levels may provide a multipronged approach to effective therapies for FRDA. Indeed, a recent study suggests that buffering the oxidative stress associated with FRDA using gold quantum cluster therapy reduced ROS, decreased autophagy, and increased Fxn protein expression providing a novel therapeutic strategy to delay disease progression in FRDA (73). This study along with others and our work reported here suggests that there may be novel therapeutic approaches to reduce disease progression in FRDA.

**Experimental procedures**

**Yeast, plasmids, and growth medium**

Genotypes of strains employed in this study are listed in Table 1. The WT strains employed for these experiments were from the W303 background. Most deletion strains were created by either PCR amplifying the KanMX cassette from the homozygous diploid deletion collection (Research Genetics) or created by either PCR amplifying the KanMX cassette from the W303 background. Most deletion strains were worked and discovered multiple pathways to increase Fxn levels may provide a multipronged approach to effective therapies for FRDA. Indeed, a recent study suggests that buffering the oxidative stress associated with FRDA using gold quantum cluster therapy reduced ROS, decreased autophagy, and increased Fxn protein expression providing a novel therapeutic strategy to delay disease progression in FRDA (73). This study along with others and our work reported here suggests that there may be novel therapeutic approaches to reduce disease progression in FRDA.

**Mammalian cell culture**

Fibroblasts (WT or FRDA Coriell GM03816) or rat H9C2 cardiomyocytes were grown in Dulbecco’s minimal essential medium with 10 to 15% fetal bovine serum and Pen/Strep and H9C2 with an additional 2 mM glutamine.

**Generating chromosomally integrated Yfh1-GFP yeast strains**

In order to avoid artifacts of overexpression, a GFP tag was chromosomally integrated in frame into the C terminus of the coding sequence of YFH1. The linear DNA sequence was amplified from the WT strain using primers as described in Table 2 also contained a His selectable marker used to transform both the WT and Δerg29pERG29 strains followed by transformation with a plasmid containing a GAL1-regulated ERG29. The Δerg29pERG29pGALIERG29 strain was then placed on 5'-fluoroorotic acid to allow the loss of the pERG29 plasmid. The chromosomal integration and selection of clones was confirmed via PCR as well as Western blotting.

**Cycloheximide pulse chase**

Cells were incubated with cycloheximide at a final concentration of 35 µg/ml and harvested at 0 h, 2 h, 4 h, 6 h, and 8 h time points. At each time point the A_{600} was measured to ensure that the cell count was normalized for each collection. Mitochondria were isolated from each sample as previously described. The half-life of each protein was calculated using nonlinear regression one phase decay.

**High throughput screen**

Δerg29pGALIERG29YFH1-GFP cells were grown overnight in the presence of 4% galactose. The media were made iron deficient by addition of 80 µm bathophenanthroline sulfonate with ferrous sulfate (5 mM) added back. The cells were then harvested and washed once with water before being resuspended in galactose or glucose-containing media at an A_{600} of 0.01, then seeded onto a 96-well plate (100 µl). Drugs were added at a static concentration of 10 µM using a Tecxan Evo 96 dispenser, utilizing the Spectrum Library (2560 compounds) provided by MicroSource Discovery Systems. Plates were incubated for 24 h, shaking at 30 °C. A_{600} values and fluorescence were measured at 0 h and 24 h using a Biotek Synergy plate reader. The fluorescence detection was set to the excitation/emission spectra of 380 nm/450 nm. A Z score of 0.527 was determined using Δerg29 ON (galactose) and Δerg29 OFF (glucose) as positive and negative controls, respectively. The score for the screen was then calculated using:

\[
\Delta \left( \frac{\text{Fluorescence}}{OD_{600}+1} \right)
\]

**Table 1**

| Yeast strains | Genotype | Note |
|---------------|----------|------|
| DY1457        | ura3-52, leu2-3,112, trp1-1, his3-11, 15, ade6, can1-100(oc) | This study |
| DY1457 YFH1-GFP | ura3-52, leu2-3,112, trp1-1, 15, ade6, can1-100(oc), YFH1-GFP::HIS3 | This study |
| Δerg29 pβ-estradiol (pGAL1ERG29) YFH1-GFP | ura3-52, leu2-3,112, trp1-1, his3-11, 15, ade6, can1-100(oc), Δerg29::KanMX4 pβ-estradiol (pGAL1ERG29) 6XHIS YFH1-GFP::HIS3 | This study |
| Δαpin1 YFH1-GFP | ura3-52,112, trp1-1, 15, ade6, can1-100(oc), YFH1-GFP::HIS3 Δαpin1::LEU2 | This study |
| Δerg29 pβ-estradiol (pGAL1ERG29) Δαpin1 YFH1-GFP | ura3-52,112, trp1-1, his3-11, 15, ade6, can1-100(oc) Δerg29::KanMX4 pβ-estradiol (pGAL1ERG29) 6XHIS YFH1-GFP::HIS3 Δαpin1::LEU2 | This study |
| Δerg29 pβ-estradiol (pGAL1ERG29) NFS1-GFP | ura3-52, leu2-3,112, trp1-1, his3-11, 15, ade6, can1-100(oc) Δerg29::KanMX4 pβ-estradiol (pGAL1ERG29) 6XHIS NFS1-GFP::HIS3 | This study |
| Δerg29pβ-estradiol (pGAL1ERG29) YFH1-GFP pMMT1 | ura3-52, leu2-3,112, trp1-1, his3-11, 15, ade6, can1-100(oc) Δerg29::KanMX4 pβ-estradiol (pGAL1ERG29) 6XHIS YFH1-GFP::HIS3 pMMT1 | This study |

**Table 2**

| Yeast plasmids | Note |
|----------------|------|
| pGAL1ERG29     | TRP1 |
| pMMT1          | LEU2 |
The top 42 candidates were selected for a follow-up screen with an n = 3 for each drug and then scored accordingly. After eliminating false positive compounds with intrinsic fluorescence, a concentration curve (1 μM, 5 μM, 10 μM, and 20 μM) was established using the top 18 highest scoring compounds to determine the most efficacious concentration.

**Crosslinking beads**

Crosslinked beads were created using magnetic Dynabead M-280 Sheep anti-rabbit immunoglobulin (Ig) G beads that were covalently linked to rabbit monoclonal anti-GFP anti-M-280 Sheep anti-rabbit immunoglobulin (Ig) G beads that were covalently linked to rabbit monoclonal anti-GFP antobody (Abcam; ab6556). Briefly, antibody was added to beads at a concentration of 0.2 μg per 10^7 beads. The antibody was then covalently crosslinked using 20 mM dimethyl pimelimidate in 0.2 M triethanolamine, pH 8.2, and unbound Ig was removed using 0.1 M Na citrate buffer pH 2.0.

**Mitoxontric turnover of frataxin**

Δerg29pGAL1ERG29 cells were grown in galactose overnight and then shifted to glucose to shut off ERG29 expression for time. Mitoxontric was added at a final concentration of 0.625 μM, cells incubated for 45 min at 30 °C in a roller drum, washed twice with 1 ml of ice-cold PBS, and cells resuspended in 500 μl of PBS. Mitoxontric fluorescence was detected using a BD FACSCanto running FACSDiva version 8.0 software from BD Biosciences as described previously (26). For mammalian cells, cells were incubated in 5 μM Mitoxontric in Hank’s balanced salts solution for 10 min at 37 °C, washed twice, and resuspended in 1 ml buffer prior to fluorescence detection.

**Sterol extractions**

Sterols were extracted and detected using GC-MS as previously described (26).

**RT-qPCR**

Total RNA was isolated using Agilent Technologies mini kit. The SuperScript III kit from ThermoFisher Invitrogen was used to synthesize first-strand complementary DNA from total RNA. Power SYBR Green Master mix (Life Technologies) was used on a Realplex2 thermal cycler (Eppendorf). β-Actin was used as a control housekeeping gene. The ΔΔCt method was used to compare the variation of transcripts among samples. Specificity and efficiency were checked before using this method. RT-qPCR primers used are as described in Table 3.

**Other procedures and reagents**

Reagents used in this study are described in Table 4. Protein determinations were performed using the bicinchoninic acid assay (Pierce) detection reagent from Thermo Fisher Scientific. Compounds were purchased from Microsource Discovery Systems Inc. Lon1 inhibitor CDDO-Me was obtained from Sigma. Proteins were analyzed by 4 to 20% or 15% SDS-PAGE Tris/glycine followed by Western blot analysis using Western Lightning (PerkinElmer Life Sciences). Antisera used for probing Western blots included anti-GFP (Sigma; 1:1000), antiyeast Nfs1 (1:1000), antimammalian Nfs1 (ThermoFisher; 1:1000), antimammalian Iscu (ThermoFisher; 1:1000), antiyeast Iscu (1:1000), rabbit antiyeast Isu1 (1:2000), rabbit antiyeast Isu1 (ThermoFisher; 1:1000), antimammalian Iscu (ThermoFisher; 1:1000), antiyeast Iscu (1:1000), anti-Fxn (Abcam; 1:1000), anti-GAPDH (Abcam; 1:5000), anti-VDAC (ThermoFisher; 1:1000), and antiaconitase (Sigma; 1:5000). Secondary antibodies were either peroxidase-conjugated goat anti-rabbit IgG or peroxidase-conjugated goat antimouse IgG (Jackson ImmunoResearch Laboratories; 1:5000). Western blots were quantified using NIH Fiji software.

**Statistics**

All experiments were performed a minimum of n = 3 times with many individual experiments including multiple biologic replicates as noted in the figure legends. Statistical analyses were performed using Student’s t test with significance set at p ≤ 0.05, where p ≤ 0.05 is shown as *, p ≤ 0.01 as **, p ≤ 0.001 as ***, and p ≤ 0.0001 as ****.
Mitochondrial turnover of frataxin

### Table 4

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|--------------------|-------------|------------------------|
| **Cell Line (Homo sapiens)**      | WT fibroblasts | ATCC               |             |                        |
| **Cell Line (Homo sapiens)**      | FRDA fibroblasts | Coriell           | GM03816     |                        |
| **Cell Line (Rattus norvegicus)** | H1C2 cardiomyocytes | Franklin Lab      |             |                        |
| **Chemical compound, drug**       | Cycloheximide | Sigma              | CAT#11203D  |                        |
| **Chemical compound, drug**       | BPS (bathophenanthroline sulfonate) | Sigma             | CAT#21667   | 20 mM                  |
| **Chemical compound, drug**       | Ferrous sulfate | Sigma             | CAT#7782-63-0 | 5 μM                |
| **Chemical compound, drug**       | Dynabead M-280 Sheep anti-rabbit IgG | ThermoFisher      | CAT#45950   | 1:5000                 |
| **Chemical compound, drug**       | Dimethyl pimelimidate | ThermoFisher      | CAT# PAS-57018 | 1:5000             |
| **Chemical compound, drug**       | Triethanolamine | ThermoFisher      | CAT# PAS-19269 | 1:10,000             |
| **Chemical compound, drug**       | MitoSOX | ThermoFisher      | CAT# PA1-954A | 1:10,000             |
| **Chemical compound, drug**       | CDDO-Me | Jackson Immuno      |             |                        |
| **Chemical compound, drug**       | Screen compound library | Research         |             |                        |
| **Commercial assay or kit**       | Agilent Tech. Mini RNA kit | Prod |             |                        |
| Antibody                          | Rabbit anti-GFP | Abcam           | Ab6556      | 0.2 μg/10^7 beads      |
| Antibody                          | Mouse anti-GFP | Sigma            | SKU11814460001 | 1:1000             |
| Antibody                          | Rabbit anti-Nfs1 (yeast) | ThermoFisher    | CAT#559500  | 1:1000                 |
| Antibody                          | Rabbit anti-Nfs1 (mammalian) | Abcam             | AB175402    | 1:1000                 |
| Antibody                          | Rabbit antiyeast Isu1 | Abcam           | AB#45-100  | 1:1000                 |
| Antibody                          | Rabbit antimammalian Iscu | ThermoFisher    | CAT# PAS-70181 | 1:5000             |
| Antibody                          | Mouse antiyeast Porin | ThermoFisher    | CAT# PAS-19269 | 1:5000             |
| Antibody                          | Rabbit anti-Fxn | ThermoFisher      | CAT# PA1-954A | 1:10,000             |
| Antibody                          | Rabbit anti-GAPDH | Jackson Immuno   |             |                        |
| Antibody                          | Rabbit antiaconitase 2 | Jackson Immuno |             |                        |
| Antibody                          | Rabbit anti-VDAC | Jackson Immuno   |             |                        |
| Antibody                          | Secondary peroxidase conjugated antibodies | Research       |             |                        |
| **Commercial assay or kit**       | SuperSignal West Femto | ThermoFisher    | CAT#34095  | 1:5000                 |
| **Commercial assay or kit**       | Western lighting plus ECL | PerkinElmer    | NEL104001EA |                        |
| **Software, algorithm**           | NIH Fiji | Imagej.net/fiji |             |                        |
| **Software, algorithm**           | GraphPad Prism Version 9.0.1 | GraphPad.com |             |                        |

### Data availability

All data are contained within the article.

### Supporting information—This article contains supporting information.

### Acknowledgments—The authors thank Jerry Kaplan, Dennis Winge and Paul Sigala for critically reading the article and the University of Utah Metals Interest Group and Centers for Iron and Heme Disorders (CIHD) for critical feedback.

### Author contributions—P. T. H. and D. M. W. formal analysis; P. T. H., L. L., and X. J. investigation; P. T. H. and D. M. W. writing—original draft.

### Funding and additional information—This study was supported by funding from Friedrich Ataxia Research Alliance (FARA) grant 10047373 and by a Pilot and Feasibility grant from the DRC at Washington University, St Louis, Mo, Grant No. P30 DK020579 to D. M. W.

### Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

### Abbreviations—The abbreviations used are: 4'-OHC, 4'-hydroxycalchone; CDDO, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid 9; CPCL, cetylpyridinium chloride; DBM, dibenzoylmethane; DDTS, 4,4-diisothiocyanostilbene-2,2-sulfonic acid; FDA, Food and Drug Administration; FeNTA, Fe-nitrotriacetic acid; FRDA, Friedreich’s ataxia; Fxn, frataxin; Ig, immunoglobulin; ISC, Fe–S cluster; NrF2, nuclear factor erythroid 2–related factor 2; ROS, reactive oxygen species; RT-qPCR, reverse transcription quantitative PCR.

### References

1. Braymer, J. J., and Lill, R. (2017) Iron-sulfur cluster biogenesis and trafficking in mitochondria. *J. Biol. Chem.* 292, 12754–12763
2. Rouault, T. A. (2015) Mammalian iron-sulphur proteins: Novel insights into biogenesis and function. *Nat. Rev. Mol. Cell Biol.* 16, 45–55
3. Rouault, T. A., and Tong, W. H. (2008) Iron-sulfur cluster biogenesis and human disease. *Trends Genet.* 24, 398–407
4. Smith, F. M., and Kosman, D. J. (2020) Molecular defects in friedreich’s ataxia: Convergence of oxidative stress and cytoskeletal abnormalities. *Front. Mol. Biosci.* 7, 569293
5. Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Goliak, P., Procaccio, V., Patel, M., Drapier, J. C., Koenig, M., and Puccio, H. (2005) Friedreich ataxia: The oxidative stress paradox. *Hum. Mol. Genet.* 14, 463–474
6. Pandolfo, M. (2009) Friedreich ataxia: The clinical picture. *J. Neurol.* 256, 3–8
7. Clark, E., Johnson, I., Dong, Y. N., Mercado-Ayon, E., Warren, N., Zhai, M., Milliman, E., Salovin, A., Lin, H., and Lynch, D. R. (2018) Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. *Neuronal Signal.* 2, NS20180060
8. Campuzano, V., Montermini, L., Lutz, Y., Cova, L., Hindelang, C., Jiralsperger, S., Trottier, Y., Kish, S. J., Faucheux, B., Trouillas, P., Authier, F. J., Durr, A., Mandel, J. L., Vescovi, A., Pandolfo, M., et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. *Hum. Mol. Genet.* 6, 1771–1780
9. Campuzano, V., Montermini, L., Molto, M. D., Pianese, L., Cossee, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., Zara, F., Canizares, J., Koutnikova, H., Bidichandani, S. I., Gellera, C., Canares, J., Koutnikova, H., Bidichandani, S. I., Gellera, C., et al. (1996) Friedreich’s ataxia: The oxidative stress paradox. *Hum. Mol. Genet.* 5, 275, 396–407
10. Fasth, J. B., Cole, M., and Lemieux, B. (1980) The cardiomyopathy of Friedreich’s ataxia morphological observations in 3 cases. *Can. J. Neurol. Sci.* 7, 389–396
11. Bradley, J. L., Blake, J. C., Chamberlain, S., Thomas, P. K., Cooper, J. M., and Schapira, A. H. (2000) Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia. *Hum. Mol. Genet.* 9, 275–282
Mitochondrial turnover of frataxin

12. Delatycz, M. B., Camakaris, J., Brooks, H., Evans-Whipp, T., Thorburn, D. R., Williamson, R., and Forrest, S. M. (1999) Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45, 673–675

13. Wong, A., Yang, J., Cavadini, P., Geller, C., Lonnerdal, B., Tanori, F., and Cortopassi, G. (1999) The Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425–430

14. Miranda, C. I., Santos, M. M., Ohshima, K., Smith, M., Li, L., Bunting, M., Cossee, M., Koenig, M., Sequeiros, I., Kaplan, J., and Pandolfo, M. (2002) Frataxin knockin mouse. FEBS Lett. 521, 291–297

15. Fox, N. G., Yu, X., Feng, X., Bailey, H. J., Martelli, A., Nabhan, J. F., Strain-Damerell, C., Bulawa, C., Yue, W. W., and Han, S. (2019) Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism. Nat. Commun. 10, 2210

16. Patra, S., and Barondeau, D. P. (2019) Mechanism of activation of the human cysteine desulfurase complex by frataxin. Proc. Natl. Acad. Sci. U. S. A. 116, 14921–14930

17. Bridwell-Rabb, J., Fox, N. G., Tsai, C. L., Winn, A. M., and Barondeau, D. P. (2014) Human frataxin activates Fe-S cluster biosynthesis by facilitating sulfur transfer chemistry. Biochemistry 53, 4904–4913

18. Chiang, S., Huang, M. L. H., Park, K. C., and Richardson, D. R. (2020) Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, friedreich’s ataxia. Free Radic. Biol. Med. 159, 177–188

19. Pallardo, F. V., Pagano, G., Rodriguez, L. R., Gonzalez-Cabo, P., Lyakhovitch, A., and Trifogli, M. (2020) Friedreich ataxia: Current state-of-the-art, and future prospects for mitochondrial-focused therapies. Transl. Res. 239, 135–141

20. Cendanyan, A., Yunisova, G., Cakar, A., Durmus, H., Basak, A. N., Parmar, Y., and Battalolu, E. (2020) The first biallelic missense mutation in the FXN gene in a consanguineous Turkish family with Charcot-Marie-Tooth-like phenotype. Neurogenetics 21, 73–78

21. Clark, E., Butler, J. S., Isaacs, C. J., Napierala, M., and Lynch, D. R. (2017) Selected missense mutations impair frataxin processing in Friedreich ataxia. Ann. Clin. Transl. Neurol. 4, 575–584

22. Li, H., Gakh, O., Smith, D. Y., Ranatunga, W. K., and Isaya, G. (2013) Human frataxin activates Fe-S cluster formation by facilitating sulfur transfer chemistry. Proc. Natl. Acad. Sci. U. S. A. 110, 17129–17134

23. Pandey, A., Gordon, D. M., Pain, J., Stemmler, T. L., Dancis, A., and Pain, D. (2013) Frataxin directly stimulates mitochondrial cysteine desulfurase by exposing substrate-binding sites, and a mutant Fe-S cluster scaffold protein with frataxin-bypassing ability acts similarly. J. Biol. Chem. 288, 36773–36786

24. Benini, M., Fortuni, S., Condo, I., Alfeldi, G., Malisan, F., Toschi, N., Serio, D., Massaro, D. S., Arcuri, G., Testi, R., and Rufini, A. (2017) E3 ligase RNF126 directly ubiquitinates frataxin, promoting its degradation: Identification of a potential therapeutic target for friedreich ataxia. Cell Rep. 18, 2007–2017

25. Rufini, A., Cavallo, F., Condo, I., Fortuni, S., De Martino, G., Incani, O., Di Venere, A., Benini, M., Massaro, D. S., Arcuri, G., Serio, D., Malisan, F., and Testi, R. (2015) Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the acentose defect in Friedreich ataxia cells. Neurobiol. Dis. 75, 91–99

26. Rui, Y., Langer, T., and Lopez-Otin, C. (2015) New roles for mitochondrial frataxin proteins in health, ageing and disease. Nat. Rev. Mol. Cell Biol. 16, 345–359

27. Koppen, M., and Langer, T. (2007) Protein degradation within mitochondria: Versatile activities of AAA proteases and other peptidases. Crit. Rev. Biochem. Mol. Biol. 42, 221–242

28. Leidhold, C., and Voos, W. (2007) Chaperones and proteases–guardians of protein integrity in eukaryotic organelles. Annu. N. Y Acad. Sci. 1113, 72–86

29. Tatsuta, T., and Langer, T. (2008) Quality control of mitochondria: Protection against neurodegeneration and ageing. EMBO J. 27, 306–314

30. Hamon, M. P., Bulteau, A. L., and Friguet, B. (2015) Mitochondrial proteases and protein quality control in ageing and longevity. Ageing Res. Rev. 23, 56–66

31. Bayot, A., Gareil, M., Rogowska-Wrzesinska, A., Roepstorff, P., Friguet, B., and Bulteau, A. L. (2010) Identification of novel oxidized protein substrates and physiological partners of the mitochondrial ATP-dependent Lon-like protease Pim1. J. Biol. Chem. 285, 11445–11457

32. Li, K. (2019) Iron pathophysiology in friedreich’s ataxia. Adv. Exp. Med. Biol. 1173, 125–143

33. Fu, X., Eggert, M., Yoo, S., Patel, N., Zhong, J., Steinke, I., Govindaraju, M., Turuntya, E. A., Mouli, S., Panizzi, P., Beyers, R., Denney, T., Arnold, R., and Amin, R. H. (2020) The cardioprotective mechanism of phenyl-alanine amidohydrolase (PAE) against doxorubicin-induced cardiotoxicity involves frataxin. Front. Pharmacol. 11, 574656

34. Rouault, T. A. (2016) Mitochondrial iron overload: Causes and consequences. Curr. Opin. Genet. Dev. 38, 31–37

35. Puccio, H., Simon, D., Cossee, M., Criqui-Filié, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P., and Koenig, M. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve
Mitochondrial turnover of frataxin

defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27, 181–186
49. Ngo, J. K., Pomatto, L. C., and Davies, K. J. (2013) Upregulation of the mitochondrial Lon Protease allows adaptation to acute oxidative stress but dysregulation is associated with chronic stress, disease, and aging. Redox Biol. 1, 258–264
50. Gibellini, L., Pinti, M., Bartolomeo, R., De Biasi, S., Cormio, A., Muscico, C., Carnevale, G., Pecorini, S., Nasi, M., De Pol, A., and Cossarizza, A. (2015) Inhibition of Lon protease by triterpenoids alters mitochondria and is associated to cell death in human cancer cells. Oncotarget 6, 25466–25483
51. Bota, D. A., and Davies, K. J. (2002) Lon protease preferentially degrades oxidized mitochondrial aconitate by an ATP-stimulated mechanism. Nat. Cell Biol. 4, 674–680
52. Bota, D. A., Van Remmen, H., and Davies, K. J. (2002) Modulation of Lon protease activity and aconitate turnover during aging and oxidative stress. FEBS Lett. 532, 103–106
53. Ciesielski, S. J., Schilke, B., Marszalek, J., and Craig, E. A. (2016) Protection of mitochondrial Lon Protease allows adaptation to acute oxidative stress in Friedreich ataxia. EMBO Mol. Med. 9, 1822, 221–225
54. Bulteau, A. L., Planamente, S., Jornea, L., Dur, A., Lesuisse, E., Camadro, J. M., and Aucelle, F. (2012) Changes in mitochondrial glutathione levels and protein thiol oxidation in yfh1 yeast cells and the lymphoblasts of patients with Friedreich’s ataxia. Biochim. Biophys. Acta 1822, 212–225
55. Marobbio, C. M., Pisano, I., Porcelli, V., Lasorsa, F. M., and Palmieri, L. (2012) Rapamycin reduces oxidative stress in frataxin-deficient yeast cells. Mitochondrion 12, 156–161
56. Bodeaer, N., Le Quan Sang, K. H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalbard, J. C., Munnich, A., and Cabanchik, Z. I. (2007) Selective iron chelation in friedreich ataxia: Biological and clinical implications. Blood 110, 401–408
57. Rotig, A., Sidi, D., Munnich, A., and Rustin, P. (2002) Molecular insights into Friedreich’s ataxia and antioxidant-based therapies. Trends Mol. Med. 8, 221–224
58. D’Oria, V., Petriti, S., Travaglini, L., Priori, C., Piemarini, E., Petriti, S., Carletti, B., Bertini, E., and Piemonte, F. (2013) Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons. Int. J. Mol. Sci. 14, 7853–7865
59. Paupe, V., Dass, E. P., Goncalves, S., Aucelle, F., Lonn, M., Holmgren, A., and Rustin, P. (2009) Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 4, e4253
60. Chang, H. C., Wu, R., Shang, M., Sato, T., Chen, C., Shapiro, J. S., Liu, T., Thakur, A., Sawicki, K. T., Prasad, S. V., and Ardehali, H. (2012) Reduction in mitochondrial iron alleviates cardiac damage during injury. EMBO Mol. Med. 6, 247–267
61. Ichikawa, Y., Bayeva, M., Ghanefar, M., Potini, V., Sun, L., Mutharasan, R. K., Wu, R., Khechaduri, A., Jaira Naik, T., and Ardehali, H. (2012) Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc. Natl. Acad. Sci. USA 109, 4152–4157
62. Cunha-Oliveira, T., Ferreira, L. L., Coelho, A. R., Deus, C. M., and Oliveira, P. J. (2018) Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes. Toxicol. Appl. Pharmacol. 348, 1–13
63. Zhao, L., and Zhang, B. (2017) Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci. Rep. 7, 44735
64. Guillou, B., Bulteau, A. L., Wattenhofer-Donze, M., Schmucker, S., Frigué, B., Puccio, H., Drapier, J. C., and Bouton, C. (2009) Frataxin deficiency causes upregulation of mitochondrial Lon and ClpP proteases and severe loss of mitochondrial Fe-S proteins. FEBS J. 276, 1036–1047
65. Correa, A. R., Ow, S. Y., Wright, P. C., and Gomez, C. M. (2009) The conserved Trp155 in human frataxin as a hotspot for oxidative stress related chemical modifications. Biochim. Biophys. Res. Commun. 390, 1007–1011
66. Llorens, J. V., Soriano, S., Calap-Quintana, P., Gonzalez-Cabio, P., and Molto, M. (2019) The role of iron in friedreich’s ataxia: Insights from studies in human tissues and cellular and animal models. Front. Neurosci. 13, 75
67. Pandolfi, M., Arpa, J., Delatycki, M. B., Le Quan Sang, K. H., Mariotti, C., Munnich, A., Sanz-Gallego, I., Tai, G., Tarnopolsky, M. A., Taroni, F., Spino, M., and Tricta, F. (2014) Deferiprone in friedreich ataxia: A 6-month randomized controlled trial. Ann. Neurol. 76, 509–521
68. Runko, A. P., Griswold, A. J., and Min, K. T. (2008) Overexpression of frataxin in the mitochondria increases resistance to oxidative stress and extends lifespan in Drosophila. FEBS Lett. 582, 715–719
69. Kim, M. J., Kim, D. W., Yoo, K. Y., Sohn, E. J., Jeong, H. J., Kang, H. W., Shin, M. J., Ahn, E. H., An, J. J., Kwon, S. W., Kim, Y. N., Won, M. H., Cho, S. W., Park, J., Eum, W. S., et al. (2010) Protective effects of transduced PEP-1-Frataxin protein on oxidative stress-induced neuronal cell death. J. Neurol. Sci. 298, 64–69
70. Kim, M. J., Kim, D. W., Jeong, H. J., Sohn, E. J., Shin, M. J., Ahn, E. H., Kwon, S. W., Kim, Y. N., Kim, D. S., Park, J., Eum, W. S., Hwang, H. S., and Choi, S. Y. (2012) Tat-Frataxin protects dopaminergic neuronal cells against MPTP-induced toxicity in a mouse model of Parkinson’s disease. Biochimie 94, 2448–2456
71. Belbella, B., Reutenauer, L., Messadegq, N., Monassier, L., and Puccio, H. (2020) High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol. Ther. Methods Clin. Dev. 19, 120–138
72. Navarro, J. A., Llorens, J. V., Soriano, S., Botella, J. A., Schnuwyly, S., Martinez-Sebastian, M. J., and Molto, M. D. (2011) Overexpression of human and fly frataxins in Drosophila provokes deleterious effects at biochemical, physiological and developmental levels. PLoS One 6, e21017
73. Villa, C., Legato, M., Umbach, A., Riganti, C., Jones, R., Martino, B., Boido, M., Medana, C., Facchinetti, I., Barni, D., Pinto, M., Arguello, T., Belicchi, M., Fagioli, G., Liaci, C., et al. (2021) Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia. Sci. Transl. Med. 13, eabe1633
74. Amberg, D. C., Botstein, D., and Beasley, E. M. (1995) Precise gene deletion in Saccharomyces cerevisiae by double fusion polymerase chain reaction. Yeast 11, 1275–1280
75. Li, L., and Kaplan, J. (2004) A mitochondrial-vacuolar signaling pathway in yeast that affects iron and copper metabolism. J. Biol. Chem. 279, 33653–33661